

For people with Alagille syndrome...

BATTLE BILE ACID BUILDUP*

Take down cholestatic pruritus.



*LIVMARLI is an ileal bile acid transporter (IBAT) inhibitor that interrupts bile acids from going back into the liver. In doing so, LIVMARLI lowers the amount of bile acids in the body because more bile acids are removed in feces. The way LIVMARLI improves cholestatic pruritus is not completely known.

ONE AND ONLY

Once-daily LIVMARLI is the **only FDA-approved medicine** for cholestatic pruritus (itch) in patients with Alagille syndrome who are **3 months of age and older**.

WHAT IT DOES

LIVMARLI targets and inhibits something in your body called the ileal bile acid transporter (IBAT). In doing so, **LIVMARLI lowers bile acids in the body (as measured by levels in the blood)**.



EARLY ITCH IMPROVEMENTS WITH LASTING RESULTS

For many patients taking LIVMARLI, itch relief was seen **at the very first assessment**.[†]

In the clinical study, patients who stayed on LIVMARLI long term (up to 4 years) saw **lasting itch relief**.



HELPING PATIENTS FOR YEARS

Backed by more than 5 years of data,[‡] LIVMARLI has a well-known safety record in patients with the itch in Alagille syndrome.

Over the last 6+ years, **LIVMARLI has been used by 500+ patients to battle bile acid buildup**.[§]



GETTING STARTED AND FINDING SUPPORT IS EASY

96% of patients are approved for LIVMARLI by their insurance^{||} and pay **\$10 or less per fill**.^{††}

Mirum Access Plus offers resources, education, and services to **help you start and stay on LIVMARLI**.

To learn more about LIVMARLI and cholestatic pruritus in Alagille syndrome, check out our full [Patient Brochure](#).

GET CONNECTED WITH PEERS



Hear the stories of real patients and their caregivers, and learn more about their experience with cholestatic pruritus and LIVMARLI.

To watch their LIVMARLI stories, check out these [Patient Videos](#).



Chat with the caregivers and parents featured in the Patient Videos through the LIVMARLI Peer Program.

To get started, register today at LIVMARLIPeerProgram.com.

[†]Itch relief was first assessed at Week 3.

[‡]From extended observation of patients taking LIVMARLI after completing a placebo-controlled study.

[§]Number includes all patients with cholestatic pruritus in Alagille syndrome treated with LIVMARLI in clinical studies, as well as those treated in the United States commercially and through the expanded access program.

^{||}Data from 1/1/2022 to 11/30/2022.

^{††}Exceptions apply for some patients, including those with TRICARE insurance.

Please see **Important Safety Information on the back and full Patient Information for LIVMARLI**.

 **Livmarli**[®]
(maralixibat) oral solution

IMPORTANT SAFETY INFORMATION

What are the possible side effects of LIVMARLI?

LIVMARLI can cause serious side effects, including:

Changes in liver tests. Changes in certain liver tests are common in patients with Alagille syndrome but may worsen during treatment with LIVMARLI. These changes may be a sign of liver injury and can be serious. Your health care provider should do blood tests before starting and during treatment to check your liver function. Tell your health care provider right away if you get any signs or symptoms of liver problems, including:

- nausea or vomiting
- skin or the white part of the eye turns yellow
- dark or brown urine
- pain on the right side of the stomach (abdomen)
- loss of appetite

Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea, stomach pain, and vomiting during treatment. Tell your health care provider right away if you have any of these symptoms more often or more severely than normal for you.

A condition called **Fat Soluble Vitamin (FSV) Deficiency** caused by low levels of certain vitamins (vitamins A, D, E, and K) stored in body fat. FSV deficiency is common in patients with Alagille syndrome but may worsen during treatment. Your health care provider should do blood tests before starting and during treatment.

Other common side effects reported during treatment were gastrointestinal bleeding and bone fractures.

Tell your health care provider about all medicines that you take. LIVMARLI may affect the way some other medicines work, and some other medicines may affect the way LIVMARLI works. If you take a medicine that lowers cholesterol by binding bile acids, such as cholestyramine, colestevlam, or colestipol, take it at least 4 hours before or 4 hours after you take LIVMARLI.

LIVMARLI is taken by mouth, 1 time each day, 30 minutes before a meal in the morning. Be sure to use the provided oral dosing dispenser to accurately measure the dose of medicine.

These are not all of the possible side effects of LIVMARLI. Call your health care provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

INDICATION

LIVMARLI is a prescription medicine used to treat cholestatic pruritus (itch) in patients with Alagille syndrome 3 months of age and older. It is not known if LIVMARLI is safe and effective in children under 3 months of age or in adults 65 years and older.

Please see full [Patient Information](#) for LIVMARLI.

**BATTLE BILE
ACID BUILDUP!**



Talk to your doctor today to learn more and visit www.LIVMARLI.com.



© 2023 – Mirum Pharmaceuticals, Inc.
All rights reserved. US-LIV-2200291 03/2023

